Carregant...
Will the potential of peroxisome proliferator‐activated receptor agonists be realized in the clinical setting?
Drugs targeting both peroxisome proliferator‐activated receptor‐gamma (PPAR‐γ) agonists (the thiazolidinediones) and PPAR‐α (the fibrates) have already been developed for clinical use. However, the thiazolidinediones, currently prescribed to treat hyperglycemia and improve peripheral insulin resista...
Guardat en:
| Publicat a: | Clin Cardiol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley Periodicals, Inc.
2007
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6654069/ https://ncbi.nlm.nih.gov/pubmed/15470905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.4960271603 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|